Skip to main content
. Author manuscript; available in PMC: 2022 Sep 1.
Published in final edited form as: Adv Drug Deliv Rev. 2021 Jul 21;176:113884. doi: 10.1016/j.addr.2021.113884

Figure 2. Diselenide-containing nanoparticles combining treatment of chemotherapy, radiotherapy, and immunotherapy.

Figure 2.

(A) Schematic illustration of DOX loaded diselenide-containing polymers for combination therapy. (B) 77 Se-NMR spectra indicating the formation of seleninic acid under γ-radiation. (C) Flow cytometry spectra demonstrating the generation of ROS. (D) Schematic illustration of pemetrexed loaded diselenide-containing self-assembled NPs for combination therapy. (E) Lactate dehydrogenase assay indicating the cell death rates of MDA-MB-231 cells co-cultured with NK92 cells. (F) ELISA results exhibiting the IFN-γ levels produced by NK92 cells in co-culture system. Copyright 2020 WILEY-VCH. [31–32]